Shell Asset Management Co. acquired a new stake in shares of Bioventus Inc. (NYSE:BVS – Get Rating) in the second quarter, HoldingsChannel.com reports. The firm acquired 13,585 shares of the company’s stock, valued at approximately $93,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Walleye Capital LLC bought a new stake in Bioventus during the 2nd quarter valued at about $77,000. Royce & Associates LP increased its stake in Bioventus by 0.8% during the 2nd quarter. Royce & Associates LP now owns 1,958,785 shares of the company’s stock valued at $13,359,000 after purchasing an additional 15,602 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Bioventus by 1,083.9% in the second quarter. Envestnet Asset Management Inc. now owns 162,185 shares of the company’s stock worth $1,106,000 after acquiring an additional 148,486 shares during the period. Stephens Inc. AR grew its stake in shares of Bioventus by 45.5% in the second quarter. Stephens Inc. AR now owns 340,901 shares of the company’s stock worth $2,325,000 after acquiring an additional 106,555 shares during the period. Finally, First Horizon Advisors Inc. bought a new stake in shares of Bioventus in the second quarter worth approximately $50,000. 44.62% of the stock is currently owned by institutional investors.
Bioventus Stock Performance
Shares of NYSE BVS opened at $1.90 on Friday. The firm has a 50 day moving average of $6.39 and a 200 day moving average of $7.65. The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $147.16 million, a price-to-earnings ratio of -6.79 and a beta of 1.85. Bioventus Inc. has a 12-month low of $1.65 and a 12-month high of $15.57.
Analyst Upgrades and Downgrades
Bioventus Company Profile
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.